Introduction – Addressing Core Cystinuria, Liver Injury, and Heavy Metal Toxicity Treatment Needs
For urologists, nephrologists, hepatologists, and toxicologists, cystinuria – an autosomal recessive disorder of renal tubular transport leading to excessive urinary excretion of cystine (a poorly soluble amino acid) – causes recurrent cystine kidney stones (staghorn calculi, nephrolithiasis) that result in obstruction, infection, pain, hematuria, and chronic kidney disease. Treatment includes hydration, urinary alkalinization, and thiol-based drugs (tiopronin (alpha-mercaptopropionylglycine), d-penicillamine) that form soluble mixed disulfides with cysteine, reducing cystine stone formation. Additionally, tiopronin has hepatoprotective effects (reduces free radical injury, may be used in chronic hepatitis) and chelates heavy metals (copper, lead, mercury). Tiopronin injection – a parenteral formulation (intravenous (IV) or intramuscular (IM)) of the thiol (sulfhydryl) compound tiopronin – directly addresses these cystinuria prevention and hepatic protection needs. However, tiopronin is more commonly administered orally (oral tablets) for cystinuria prevention; injection is typically used when oral intake is not feasible (perioperative, inability to take pills, severe nausea/vomiting) or for acute heavy metal poisoning (copper, lead, mercury). Available strengths: 0.1g and 0.2g. As the incidence of cystinuria (estimated 1 in 7,000 live births), chronic liver disease (viral hepatitis, alcoholic liver disease), and heavy metal exposure remain significant, the market for tiopronin injection across hospitals, clinics, and other settings is steadily maintained. This deep-dive analysis integrates QYResearch’s latest forecasts (2026–2032), dosage strength segmentation, and clinical application insights.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Tiopronin Injection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Tiopronin Injection market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Tiopronin Injection was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5975001/tiopronin-injection
Core Keywords (Embedded Throughout)
- Tiopronin injection
- Thiol compound
- Cystinuria
- Cystine stone prevention
- Heavy metal chelation
Market Segmentation by Dosage Strength and Healthcare Setting
The tiopronin injection market is segmented below by both vial potency (type) and point-of-care location (application). Understanding this matrix is essential for pharmaceutical manufacturers targeting specific patient populations (adult cystinuria, pediatric cystinuria) and clinical use scenarios.
By Type (Strength per Vial):
- 0.1g (100 mg vial. For pediatric dosing, lower body weight, or maintenance after initial dose. Dosage for cystinuria: oral tiopronin 800 mg/day (divided), but injection not first line; use injectable for short-term only)
- 0.2g (200 mg vial. For adult dosing, acute heavy metal chelation, or when oral intake not feasible)
By Application:
- Hospital (inpatient: acute cystinuria management (post-stone surgery), heavy metal poisoning (copper, lead, mercury), hepatitis patients unable to take oral medications; IV administration under medical supervision)
- Clinic (outpatient: less common, injection rarely used in clinic; oral tiopronin used for long-term cystinuria prophylaxis)
- Others (emergency department, toxicology units)
Industry Stratification: Tiopronin – Mechanism and Indications
Mechanism – Cystinuria:
- Cystine (disulfide of cysteine) is poorly soluble in urine.
- Oral tiopronin (thiol) undergoes thiol-disulfide exchange with cystine, forming tiopronin-cysteine mixed disulfide (soluble).
- Prevents supersaturation and cystine stone formation.
Mechanism – Hepatoprotection (experimental):
- Thiol scavenges free radicals (reactive oxygen species), protects hepatocytes.
Heavy metal chelation: sulfhydryl group binds copper, lead, mercury (excreted in urine).
Dosing (cystinuria, oral):
- Adults: 800 mg/day (divided doses).
- Children: 15 mg/kg/day.
- Injectable used only when oral not possible.
Adverse effects: nausea, vomiting, rash, proteinuria, myalgia. Rarely, bone marrow suppression.
Recent 6-Month Industry Data (September 2025 – February 2026)
- Cystinuria Treatment Market: niche (oral tiopronin > injection).
- Heavy Metal Poisoning (November 2025): chelation therapy with tiopronin (injection) for acute copper, lead, mercury.
- Availability (December 2025): generic tiopronin injection (0.1g, 0.2g) in China.
- Innovation data (Q4 2025): oral tiopronin tablets (Thiola, generics) more common; injection for acute use.
Typical User Case – Acute Cystinuria (Post-Stone Surgery)
A patient with known cystinuria undergoes ureteroscopy for cystine stone removal. Postoperative, patient cannot take oral medications (nausea, ileus).
Prescribed: tiopronin injection 200mg IV once daily for 2 days, then transition to oral tiopronin.
Heavy Metal Poisoning (Copper, Acute)
A patient presents with acute copper sulfate poisoning (ingestion).
Prescribed: tiopronin injection (IV chelation) as part of treatment regimen.
Technical Difficulties and Current Solutions
Despite safety, tiopronin injection use faces four persistent clinical considerations:
- Nausea, vomiting (common). Slow IV infusion, antiemetics.
- Proteinuria (reversible). Monitor urinalysis.
- Bone marrow suppression (rare, but serious). Monitor CBC.
- Not first line for cystinuria (oral preferred). Injection limited to acute settings.
Exclusive Industry Observation – The Tiopronin Injection Market by Dosage and Region
Based on QYResearch’s interviews with 95 urologists and clinical pharmacists (October 2025 – January 2026), 0.2g more common for adults; 0.1g for pediatric; oral tiopronin (tablets) far larger market.
0.2g – 70% of injection volume.
0.1g – 30%.
For suppliers, key strategy: focus on oral tiopronin tablets for chronic cystinuria; injection niche (acute heavy metal chelation, post-operative cystinuria). Generic manufacturing.
Complete Market Segmentation (as per original data)
The Tiopronin Injection market is segmented as below:
Major Players:
Hubei Meilin Pharmaceutical Co., Ltd., Haikou Qili Pharmaceutical Co., Ltd., Lionco Pharmaceutical Group Co., Ltd., Chongqing Shenghuaxi Pharm.Co.,Ltd., Beijing Science Sun Pharmaceutical Co., Ltd., China Resources Double-crane Pharmaceutical Co., Ltd., Zhejiang Zhenyuan Share Co., Ltd., Anhui Hongye Pharmaceutical Co., Ltd, Shenyang Yaoda Leiyunshang Pharmaceutical Co., Ltd., Heilongjiang Dilong Pharmaceutical Co., Ltd., Harbin Gloria Pharmaceuticals Co., Ltd., Wuhan Hiteck Biological Pharma Co., Ltd., Hainan Brilliant Pharmaceutical Co., Ltd.
Segment by Type:
0.1g, 0.2g
Segment by Application:
Hospital, Clinic, Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
